Regeneron Pharmaceuticals Inc. (REGN) is seeking to expand the approval of Dupixent for yet another indication – this time for children aged 6 to 11 years with moderate-to-severe asthma.The FDA is expected to announce its decision on the additional indication on October 21, 2021.Dupixent, jointly developed by Sanofi and Regeneron, is already approved for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis, as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older, and as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.The global net sales of Dupixent in 2020, which are recorded by Sanofi, were $4.04 billion, up 75% over 2019. Jefferies analysts expect the drug to achieve peak sales of $12.5 billion.REGN closed Wednesday’s trading at $606.70, up 0.28%.